Articles tagged with Cancer Stem Cells
Researchers at Cedars-Sinai identified immune system targets on cancer stem cells and created an experimental vaccine to attack them. The vaccine, which uses dendritic cells, was tested in lab mice and showed promise without causing side effects.
A new technology grows cord blood stem cells in a lab before transplant, increasing survival rates by 9.6% compared to traditional methods. Patients who received the StemEx transplants engrafted faster and were less vulnerable to infections and bleeding.
Researchers have found that prostate cancer stem cells change from basal to luminal cells as the disease progresses, rendering existing treatments less effective. This discovery could lead to more targeted therapies by targeting the evolving cancer stem cells.
Researchers at Princess Margaret Cancer Centre have identified a promising new therapeutic path for colorectal cancer by disarming the BMI-1 gene, which drives self-renewal in stem cells. Inhibiting this gene resulted in long-term and irreversible impairment of tumour growth, providing strong evidence for its clinical relevance.
Researchers discovered that doxycycline-induced neural stem cells exhibit increased proliferative activity and inhibitory differentiation similar to tumor stem cells. This suggests a possible link between neural stem cells and the origin of brain tumor stem cells.
A new study found that certain immune cells help cancer stem cells survive and thrive. This finding has significant implications for the development of targeted therapies to eliminate cancer.
Researchers discovered 10 specialized subregions within the midgut of fruit flies, each with unique stem cell functions. These regional differences may explain why some organs generate cancer frequently while others rarely. The study sheds light on the intricate relationships between tissue organization and stem cell function.
Researchers found that ZEB1 gene enables basal-type breast cancer cells to convert into aggressive tumor-forming cancer stem cells. Luminal breast cancer cells, which are less aggressive, carry the gene but have it permanently shut down.
A new study by The Endocrine Society finds that early exposure to BPA significantly increases the risk of both prostate cancer and a precancerous condition known as prostate epithelial neoplasia. The study used human prostate stem cells from organ donors to grow prostate tissue in a mouse model.
A study published in PLOS Biology reveals that a single mutation in the JAK2 gene reduces the ability of blood stem cells to self-renew without affecting their progeny daughter cells. This finding has implications for understanding how single stem cells contribute to tumor growth in cancers suspected to have a stem cell origin.
A multi-institutional team of researchers pinpointed the genetic traits of cells giving rise to gliomas, a common form of malignant brain cancer. They identified a core set of genes and pathways dysregulated during tumor progression, providing rich new potential targets for therapeutic intervention.
Researchers have identified a novel surface marker called Cd1d to isolate mammary gland stem cells with unprecedented purity. This breakthrough allows for high-degree profiling of normal and cancer stem cells, potentially leading to the development of new breast cancer drug targets.
Researchers have developed a multi-parameter sorting approach to separate healthy spermatogonial stem cells from cancerous cells, enabling the removal of malignant material during transplantation. This method shows promise for preserving fertility in male childhood cancer survivors.
Researchers have identified FOXC2 as a protein vital to the formation of cancer stem cells and the epithelial-mesenchymal transition in breast cancer. The study found that blocking FOXC2 with the FDA-approved drug sunitinib inhibited the growth of cancer stem cells and reduced metastasis in mice with triple-negative breast cancer.
The study reveals that the Notch protein activates GATA2 gene to produce hematopoietic stem cells and regulates its expression through HES-1 repressor. This basic circuit is essential for generating limited production of GATA2, necessary for hematopoietic stem cell production.
A novel cancer drug called sabutoclax appears to selectively target hard-to-reach leukemia stem cells that overexpress pro-survival protein forms. The findings suggest that pan-BCL2 inhibition may be critical for eradicating cancer stem cells in CML, and could also be beneficial for treating solid tumor cancers.
A study published in PNAS reveals that inflammation enhances the activity of enzyme ADAR1, leading to increased self-renewal and therapeutic resistance in cancer stem cells. Targeting this pathway with a small molecule inhibitor may help prevent relapse and progression of chronic myeloid leukemia.
Researchers identify protein kinase Akt as a regulator of cancer stem cell biology, linking its hyperactivation to cancer resistance. The findings suggest that targeting Akt could be a new approach for killing cancer stem cells in cancer therapy.
Researchers have isolated cancer stem cells from kidney tumors that lead to Wilms' tumours, a type of cancer typically found in the kidneys of young children. These cancer stem cells can be targeted with an antibody drug, providing a potential new approach for treating this disease.
A University of Cincinnati research team isolated and grew lung cancer stem cells in a preclinical model, offering a new avenue for investigating immunotherapy options that specifically target stem cells. This breakthrough could lead to the development of novel therapies targeting these cells and improving treatment outcomes.
The CU Cancer Center is conducting a Phase I clinical trial of OMP-54F28, a drug that targets cancer stem cells and the Wnt signaling pathway. The trial aims to assess the safety and efficacy of the agent in patients with advanced solid tumor cancers.
Researchers at Moffitt Cancer Center have discovered that microRNA miR-214 plays a critical role in regulating ovarian cancer stem cell properties. The study found that miR-214 induces the expression of a stem cell transcription factor (Nanog), leading to chemoresistance and potentially serving as a therapeutic target for ovarian cancer.
Researchers identify a subpopulation of cancer stem cells that display resistance to chemotherapy and contribute to tumor progression. The study suggests a new therapeutic strategy by targeting these cancer stem cells with a combination of standard chemotherapy and signaling pathway inhibitors.
A*STAR scientists have identified a potential drug target, miR-138, that can prevent the progression and relapse of glioblastoma multiforme, a deadly form of brain tumour. Depleting this biomarker with antimiR-138 led to complete destruction of cancer cells in vitro.
Scientists from the University of Zurich identified a key role for the Sox10 gene in promoting melanoma development and proliferation. Suppressing this gene in mice inhibited cancer growth, offering new potential therapy avenues.
A study by University of California - San Diego researchers blocks the NOTCH1 signaling pathway in cancer cells, reducing their ability to replicate and self-renew. The findings suggest that therapies targeting this pathway could be effective in treating various types of cancer stem cells.
Scientists at Queen Mary University of London have discovered a novel link between Keratin K15 and FOXM1 genes, which may lead to the development of targeted anti-cancer drugs. This breakthrough could potentially prevent cancer recurrence by targeting cancer stem cells.
Researchers have identified leukemia inhibitory factor (LIF) as a potential target to block the growth of cancer stem cells in pancreatic tumors. Blocking LIF activity has been shown to reduce the tumor's ability to regenerate and metastasize.
Researchers found that metformin effectively eliminates cancer stem cells in pancreatic cancer, leading to tumor regression and long-term survival. Combining metformin with standard chemotherapy further eradicated both cancer stem cells and differentiated cancer cells.
Researchers discovered an anti-psychotic drug, thioridazine, that selectively targets and exhausts cancer stem cells, leading to improved survival rates in leukemia patients. The compound works by encouraging cancer stem cells to differentiate into less threatening cell types.
Researchers developed a new method to identify vaccine targets for Streptococcus pneumoniae, the most common cause of bacterial meningitis. Gene therapy has shown promise in treating adenosine deaminase deficiency by correcting B cell tolerance problems and supporting treatment options for patients with severe combined immunodeficiency.
Researchers at IBN developed a miniaturized biochip, Droplet Array, to study the effect of drugs on cancer stem cells (CSCs). The new technology shows CSCs can survive chemotherapy and drive metastasis, highlighting the need for more effective cancer drugs.
Researchers at Mayo Clinic have identified a single gene, MMP-10, that promotes the development and spread of lung cancer. This discovery suggests that targeting this gene may be an effective way to treat non-small cell lung cancer.
Researchers at Vetmeduni Vienna have shown that chronic myeloid leukaemia (CML) and B-cell acute lymphoid leukaemia (B-ALL) arise from the same long-term haematopoietic stem cells. Understanding this finding is crucial for developing targeted therapies, as current treatments may not effectively target cancer stem cells.
Researchers at NIH have discovered how arsenic exposure can turn normal stem cells into cancer stem cells, spur tumor growth. This finding suggests that cancer may be a stem-cell-based disease and has implications for understanding carcinogenesis.
Scientists have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells. The study found that purified cancer stem cells strengthened the potency of antibodies and T cells that selectively targeted cancer stem cells.
Dr. Beatrice Mintz has made significant contributions to cancer research, including her work on developmental biology and genetics. Her groundbreaking studies have helped shape our understanding of stem cell behavior and the tumor microenvironment.
Researchers at UCLA's Jonsson Comprehensive Cancer Center found that radiation treatment converts normal breast cancer cells into treatment-resistant stem cells. These induced breast cancer stem cells have a 30-fold increased ability to form tumors, undermining the effectiveness of radiation therapy.
Research identifies SIRT1 as a key enzyme protecting leukemia stem cells from stress and driving cancer recurrence. Inhibiting SIRT1 selectively reduces CML stem cell survival and growth, offering a potential therapeutic target for treatment resistance.
Researchers at Wake Forest Baptist Medical Center have developed a nanotube therapy that kills breast cancer stem cells by generating heat using laser treatment. The approach has shown promise in eliminating both differentiated cells and cancer stem cells, offering new hope for a cure.
A collaboration between researchers has shown that cell senescence occurs spontaneously in melanoma cells but does not stop their growth, which is sustained by a small population of cancer stem cells. The study explains why inducing senescence alone is difficult to treat cancer cells.
A phase 1 clinical trial of cardiac stem cells has shown promising results in patients with severe heart failure after a heart attack. LVEF increased from 30.3% to 38.5% at 4 months, and further improvement was seen at 1 year.
A new therapy approach targets a self-renewal pathway in embryonic stem cells to eliminate cancer stem cells in pancreatic cancer. In mice with human pancreatic cancer tumors, the combination of Nodal/Activin pathway inhibition and chemotherapy led to 100% survival after 100 days.
Research reveals VEGF's crucial role in regulating skin cancer stem cells, which are key to sustaining tumor growth. The study also identifies Neuropilin 1 as a critical receptor in this process, highlighting new targets for cancer therapy.
Researchers identified 694 compounds that showed some activity against brain cancer stem cells, including four lead compounds that most successfully inhibited the cells. The study aims to reveal the biology of these stem cells and potentially result in a new therapy for deadly brain cancers.
A multi-institute team led by TGen will study triple-negative breast cancer, a highly aggressive form of the disease that disproportionately affects African-Americans. The research aims to uncover new ways of treating this aggressive form of breast cancer by understanding molecular makeup of breast cancer stem cells.
Researchers at UCLA found that brain cancer stem cells can change their metabolic state from glycolysis to oxidative phosphorylation, allowing them to evade treatment. This unique ability makes glioma stem cells resistant to conventional treatments, highlighting the need for new therapies targeting these cells specifically.
Researchers have found that acute myeloid leukemia (AML) contains rare cancer stem cells (LSCs) with unique properties that can predict clinical outcome. The LSC signature can identify patients who may benefit from more aggressive therapy, enabling personalized treatment approaches.
Researchers at the Broad Institute and Whitehead Institute found that cancer cells can interconvert between different types, existing in phenotypic 'states' that can change over time. This decentralized model challenges the traditional view of cancer stem cells as a hierarchical society.
Researchers at Cleveland Clinic have identified a molecular pathway that promotes brain tumor growth in malignant glioma. The study found that existing medications block this pathway and delay tumor growth in animal models, suggesting a potential new treatment option.
Researchers have discovered an enzyme in glioblastoma stem cells that allows them to grow and seed tumors. Unlike normal stem cells, these enzymes are not shared, making them a potential target for therapy. The study found that inhibiting this pathway slows the growth of brain tumors in mice, offering hope for improved treatment options.
Researchers isolate a single human blood stem cell capable of regenerating the entire blood system, offering a breakthrough for treating cancer and other diseases. The discovery enables the harnessing of these life-producing cells to treat patients more effectively.
A study published in Cancer Research found a link between the ABCB5 marker and treatment resistance in colorectal cancers. The researchers discovered that eliminating cells expressing ABCB5 is crucial for successful treatment, supporting the cancer stem cell hypothesis. This finding has significant translational and therapeutic relevance.
Researchers have successfully used oncolytic viruses to infect and kill pancreatic cancer stem cells, which are thought to cause disease recurrence and metastasis. This breakthrough could provide a potential therapy for pancreatic cancer patients, particularly those with tumors resistant to conventional chemotherapy and radiation.
Researchers at UNC Chapel Hill School of Medicine isolated normal stem cells with aggressive breast cancer properties and identified a genetic intersection that contributes to metastasis. The study suggests a new target for treating triple negative breast cancer.
Dr. Paul Sanberg, a renowned researcher in stem cell therapy, received the Everfront Award for his groundbreaking work on regenerative medicine for neurodegenerative disorders. His research expertise and initiatives in innovation and translational medicine were recognized by the symposium organizers.
Squamous cell cancers can arise from hair follicle stem cells, which were found to be more prone to developing tumors. Researchers hope this discovery will lead to specific therapies targeting cancer initiation, potentially preventing the disease before it starts.
Whitehead Institute researchers found that differentiated cells in breast tissue can convert to a stem-cell-like state, challenging scientific dogma. This behavior may have implications for cancer therapeutics and degenerative disease therapy.
Researchers have identified a gene that controls the behavior of stem cells in the intestine, which can lead to bowel cancers. The team aims to grow healthy stem cells into transplant tissues to replace damaged intestines, potentially treating patients with Crohn's disease and some cancers.
Researchers found that genes similar to those in intestinal stem cells are activated in colorectal cancer cells, predicting a higher risk of relapse. The discovery opens up new possibilities for diagnosing and treating colon cancer by targeting tumour stem cells.